about
XG-102 administered to healthy male volunteers as a single intravenous infusion: a randomized, double-blind, placebo-controlled, dose-escalating study.A more sensitive MS detector does not obviously lead to a more sensitive assay: experiences with ES-285.Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.Pharmacokinetic interaction between pyronaridine-artesunate and metoprololTrabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers.Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma.Evaluation of the use of in vitro methodologies as tools for screening new compounds for potential in vivo toxicity.Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F.Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry.Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).Liquid chromatographic assay for the cyclic depsipeptide aplidine, a new marine antitumor drug, in whole blood using derivatization with trans-4'-hydrazino-2-stilbazole.Determination of aplidin, a marine-derived anticancer drug, in human plasma, whole blood and urine by liquid chromatography with electrospray ionisation tandem mass spectrometric detection.Active eosinophilic esophagitis is associated with impaired elimination of budesonide by cytochrome P450 3A enzymes.Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice.Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease.Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies.Drug associated cutaneous vasculitis in adults in northwestern Spain.[Short-term disability: surmounting conflict through understanding].Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer.[Gastrointestinal involvement and the response to dapsone in a case of the urticarial vasculitis syndrome][The introduction of generic pharmaceutical products into Galicia]The situation of clinical pharmacology in general practice in SpainSuccessful response to captopril in severe nephrotic syndrome secondary to lupus nephritisAcute myocardial infarction associated with sildenafil[Commentary: immigration, health status, and use of primary care services][Optimising the use of exercise for the treatment of fibromyalgia]A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin® (EU and US) in healthy male subjectsPharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm StA Population Pharmacokinetic-Pharmacodynamic Model of PegfilgrastimSensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity StudiesMass balance and metabolism of the antimalarial pyronaridine in healthy volunteers
P50
Q30423728-8AD0E791-65DC-44EB-8623-9A5CFA98A24AQ31099348-681059E5-70B3-40DC-BA6F-F9F8BD31FA0EQ32073247-24359F4A-B068-4BAA-B70C-1E662C7D12FFQ33335724-4EA94295-7F03-48ED-80EE-A5EFADAF8425Q34299041-E6E3FDFF-4E5D-4157-A7E3-B9A0E485E20DQ34560520-D8AEFC42-964B-498B-A7F4-7A0D23481C79Q34580659-E2394812-6D15-47F8-92AC-7E73F832442AQ34582940-D4EA2BF4-7BF7-4A89-BCD8-2CC423EFF1E0Q35191364-09B5EE01-0E01-4CCC-9D2C-F5FC31814304Q40353033-826A089D-DF44-49FE-80A6-66D23DF5D175Q40779059-1AB488E7-AE4B-4C58-B780-0BC919986B6BQ43697309-1AF46C2B-0B5B-4D0B-A2D1-F14916AFC340Q44470649-443E37BC-A628-4A29-96FD-3FD9E105B76BQ44739469-B9A09386-AC25-4EF3-BEAC-BC05B8540CE9Q44762098-A3CF082C-C5C0-42EE-B2B5-CD10EBEC0320Q44884238-17E550B3-DDF0-4759-B9B5-F3F4CF1614EDQ45097168-50D9D0DB-3BD8-4916-91AB-BB5DD55B6D22Q46111736-0291062A-AC98-4D34-8A08-AC6153A5B0DEQ46128122-7E55B8D5-A083-42DE-A22C-00AB8CA92C9EQ46711571-880D713D-EDC9-496C-A989-064599B18CE6Q50652046-7A1D69D6-F948-43F7-9797-AD4A8D5E7DDDQ53832193-78AC5BF9-2F66-4238-A5D3-9E0552213BF0Q53866809-07CD6B5F-2A50-41DE-8424-E4A9F8C8D9B0Q67823242-4F5AAA1B-6796-49C7-BB94-66C5CD6661A0Q73475469-F802880A-99B6-4796-A224-5CB96455C228Q77506615-FC23C1C2-4CC2-485F-9F63-4373574D17D9Q77527171-2F2B4B26-FFC4-4390-89CA-C4AE54E9336FQ77719442-4146A94B-35D6-408E-A36A-81F705F6DDC0Q81284171-AD7F7D57-26C8-4D72-B856-F90597743763Q85279739-646FE913-A061-4521-9B8A-724E92655A8FQ89254714-A6ED23A8-D965-458B-9544-32C076093711Q89689953-A4DCBEAD-CD29-4301-9FDC-77A7B76F582EQ90970893-E0867A66-8C41-4070-BCE5-856130E71A6CQ91729076-9CD99049-526A-4DC6-B3A1-F7E09F59FEA4Q95560841-B6C5A3BB-91D1-4B6C-90F3-FB3ADBF1446A
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
Luis López Lázaro
@en
López Lázaro L
@ast
López Lázaro L
@es
López Lázaro L
@nl
type
label
Luis López Lázaro
@en
López Lázaro L
@ast
López Lázaro L
@es
López Lázaro L
@nl
altLabel
López Lázaro L
@en
prefLabel
Luis López Lázaro
@en
López Lázaro L
@ast
López Lázaro L
@es
López Lázaro L
@nl
P31
P496
0000-0003-0620-6133